文献速递前列腺癌

磁共振成像引导的腔内与磁共振成像-经直肠超声融合靶向前列腺穿刺活检:临床显著性前列腺癌检出率的校正比较

Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate.
PubMed 文献 · Eur Urol Oncol · 2018-09-20

该单中心回顾性分析比较了磁共振成像-经直肠超声融合靶向穿刺与腔内穿刺在异常多参数磁共振男性中临床显著性前列腺癌的检出率。共纳入腔内穿刺103例和融合穿刺300例,腔内穿刺每例患者临床显著性前列腺癌检出率更高(61% vs 47%,校正OR 2.1),临床不显著癌检出更少(11% vs 18%,OR 0.5)。作者结论认为腔内穿刺检出更多临床显著癌且更少不显著癌,但需进一步成本效用和患者结局分析。

要点

  • 腔内穿刺每例患者临床显著性前列腺癌检出率61%(63/103)高于融合穿刺联合系统穿刺47%(141/300),校正OR 2.1。
  • 腔内穿刺临床不显著癌检出率11%(11/103)低于融合穿刺18%(53/300),OR 0.5。
  • 根治性前列腺切除术后Gleason分级分组升级率腔内组17%(4/24)与融合组27%(22/82)无显著差异(p=0.55)。

核心结论

  • 磁共振成像引导的腔内穿刺比磁共振成像-经直肠超声融合靶向穿刺检出更多临床显著性前列腺癌和更少临床不显著前列腺癌。
  • 需进一步成本效用和患者结局分析。

研究设计与样本

  • 单中心、回顾性分析前瞻性生成的数据。
  • 纳入2017年5月至2018年4月间所有多参数磁共振异常并接受融合或腔内穿刺的男性。
  • 腔内穿刺队列103例,融合穿刺队列300例;Gleason分级分组2-5定义为临床显著性前列腺癌。

主要发现

  • 每例患者分析中,腔内穿刺临床显著性前列腺癌检出率61%(63/103),融合联合系统穿刺47%(141/300),校正比值比2.1(95%置信区间1.6-2.8,p<0.0001)。
  • 腔内穿刺临床不显著癌检出率11%(11/103),融合穿刺18%(53/300),比值比0.5(95%置信区间0.3-0.8,p=0.001)。
  • 接受根治性前列腺切除术者中,腔内队列术后Gleason分级分组升级17%(4/24),融合队列27%(22/82),p=0.55。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 单中心、回顾性分析。
  • 需进一步成本效用和患者结局分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With the increasing adoption of targeted prostate biopsies, it becomes important to understand the strengths and shortcomings of the techniques available for targeting suspicious lesions. OBJECTIVE: To compare clinically significant prostate cancer (csPCa) detection rate with magnetic resonance imaging-transrectal ultrasound (MRI-TRUS) fusion versus in-bore biopsy in men with abnormal multiparametric MRI (mpMRI). DESIGN, SETTING, AND PARTICIPANTS: This single-center, retrospective analysis of prospectively generated data included all men with abnormal mpMRI and fusion or in-bore biopsy between May 2017 and April 2018. Grade group (GG) 2-5 cancers were considered csPCa. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Detection of csPCa was adjusted according to patient- and lesion-related characteristics using propensity score weighting. Secondary endpoints included the detection of clinically insignificant tumors and the rate of GG upgrade from biopsy to prostatectomy specimen. Analyses were performed at patient and lesion levels. RESULTS AND LIMITATIONS: A total of 103 and 300 men were included in the in-bore and fusion cohorts, respectively. On a per-patient basis, in-bore biopsies detected a higher proportion of csPCa (61%, 63/103) than fusion plus systematic biopsies (47%, 141/300; adjusted odds ratio [OR]: 2.1, 95% confidence interval [CI]: 1.6-2.8, p<0.0001). In-bore biopsies also detected fewer (11%, 11/103) clinically insignificant cancers than fusion biopsies (18%, 53/300; OR: 0.5, 95% CI: 0.3-0.8, p=0.001). Of those who had radical prostatectomy, GG upgrade after surgery was seen in 17% (4/24) of the men in the in-bore cohort and in 27% (22/82) of the men in the fusion cohort (p=0.55). CONCLUSIONS: MRI-guided in-bore biopsies detected more clinically significant and fewer insignificant prostate cancers than MRI-TRUS fusion targeted biopsies. Further cost-utility and patient outcome analyses are needed. PATIENT SUMMARY: In-bore biopsies (where the patient is on the magnetic resonance imaging [MRI] scanner itself) detected more aggressive cancers and fewer indolent cancers than fusion (where software blends MRI and ultrasound images) biopsies. These findings may help patients and physicians choose the best biopsy approach.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Costa DN, Goldberg K, Leon AD, et al. Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate. Eur Urol Oncol. 2018. PMID: 31277776. doi:10.1016/j.euo.2018.08.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。